Recursion Pharmaceuticals, Inc.
RXRXNASDAQHealthcare● Active
$3.32
+$0.00(+0.13%)
Market Cap$1.5B
P/E Ratio—
52W High$7.18
52W Low$2.77
Recursion Pharmaceuticals, Inc.（RXRX）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · RXRX · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $74.68M | $58.84M | $43.88M | $39.68M | $10.00M |
| Cost of Revenue | $120.95M | $45.24M | $42.59M | $48.27M | $0.00M |
| Gross Profit | ($46.27M) | $13.60M | $1.29M | ($8.59M) | $10.00M |
| Gross Margin %(computed) | -61.96% | 23.12% | 2.94% | -21.66% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $425.27M | $314.42M | $241.23M | $155.70M | $135.27M |
| G&A Expenses | $176.59M | $178.18M | $110.82M | $81.60M | $57.68M |
| Total Operating Expenses | $601.86M | $492.61M | $351.35M | $237.13M | $192.78M |
| Operating Income | ($648.13M) | ($479.00M) | ($350.06M) | ($245.73M) | ($182.78M) |
| Operating Margin %(computed) | -867.87% | -814.09% | -797.84% | -619.26% | — |
| Interest Income | $22.79M | $15.76M | $19.12M | $6.25M | $0.07M |
| Interest Expense | $1.81M | $1.57M | $0.10M | $0.06M | $2.95M |
| Income Before Tax | ($644.89M) | ($464.79M) | ($332.13M) | ($239.48M) | ($186.48M) |
| Income Tax Expense | ($0.14M) | ($1.13M) | ($4.06M) | $0.00M | $0.00M |
| Net Income | ($644.76M) | ($463.66M) | ($328.07M) | ($239.48M) | ($186.48M) |
| Net Margin %(computed) | -863.35% | -788.02% | -747.71% | -603.50% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.05 |
| Wtd Avg Shares | 447.45M | 274.21M | 207.85M | 175.54M | 170.27M |
| EBITDA | ($559.38M) | ($426.72M) | ($307.63M) | ($227.66M) | ($175.12M) |
| EBITDA Margin %(computed) | -749.03% | -725.24% | -701.13% | -573.74% | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解Recursion Pharmaceuticals, Inc.
关于Recursion Pharmaceuticals, Inc.（RXRX）损益表
Recursion Pharmaceuticals, Inc.（RXRX）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，RXRX实现营收$0.07B，毛利润($0.05B)（毛利率-61.96%），净利润($0.64B)（净利率-863.35%）。
常见问题
RXRX · 4 问Recursion Pharmaceuticals, Inc.（RXRX）2025财年营收为$0.07B，同比up26.9%。
RXRX revenueRXRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08